A look back at BrightInsight's first half of 2022

Look back 2022 690x345 2x 1

The BrightInsight® Platform is supporting solutions for major on-market drug brands with a combined $30-$40B forecast for peak annual sales supporting various chronic diseases, from rare diseases to common conditions that affect hundreds of millions of people worldwide. As we come to the midpoint of the year, we're taking some time to reflect on the first half of 2022 and the many things we've accomplished over the past six months. BrightInsight has been hard at work helping biopharma and medtech companies develop and release cutting-edge digital health solutions with unprecedented speed and efficiency.

Here's a list of our most exciting accomplishments so far in 2022:







As we dive into the second half of the year, our team is excited to add to this list of milestones and continue accelerating time to market for our customers’ regulated digital health solutions.

Back to Blog